Business Description
Pharvaris is a Swiss-based biopharmaceutical company founded in 2015 and focused on developing treatments for rare conditions where patients currently have few or limited options. Its lead medicine, deucrictibant, is an oral drug designed to treat and prevent episodes of hereditary and acquired angioedema ? conditions that cause sudden, painful swelling ? and is currently being evaluated in late-stage clinical trials. The company is advancing both a capsule and a tablet form of the drug to give patients greater flexibility in how they take it.
